A subcutaneous, off-the-shelf bispecific T-cell–engaging monoclonal antibody (BCMA×CD3) that binds BCMA on myeloma cells and CD3 on T cells to activate T cells and mediate cytotoxic killing of BCMA-positive plasma cells.
Elranatamab is a bispecific monoclonal antibody that simultaneously binds BCMA on malignant plasma cells and CD3 on T cells, crosslinking them to activate T cells and trigger cytotoxic killing of BCMA-positive cells.
NO
INDIRECT
Elranatamab binds CD3 on T cells to activate and redirect them to BCMA-expressing myeloma cells; the activated T cells kill BCMA+ targets via perforin/granzyme-mediated cytotoxicity. CD3+ T cells themselves are not targeted for killing.
A human afucosylated IgG1 monoclonal antibody (AMG 451; KHK4083) administered subcutaneously that targets OX40 (CD134), blocks OX40–OX40L signaling to reduce T-cell activation and survival, and mediates ADCC to deplete OX40-positive activated T cells.
Human afucosylated IgG1 monoclonal antibody targeting OX40 (CD134) that blocks OX40–OX40L co-stimulatory signaling to reduce T-cell activation and survival, with enhanced ADCC to deplete OX40-positive activated T cells.
YES
DIRECT
Binds OX40 on activated T cells and, via its afucosylated IgG1 Fc, engages FcγRIIIa on NK cells to trigger ADCC, directly depleting OX40+ cells.
A HER2-targeted antibody–drug conjugate with a cleavable linker to a topoisomerase I inhibitor payload; binds HER2, internalizes, and releases the payload to induce DNA damage while retaining HER2 blockade and ADCC.
HER2-targeted monoclonal antibody conjugated via a cleavable linker to a topoisomerase I inhibitor; binds HER2 on tumor cells, internalizes, and releases the cytotoxic payload to inhibit Topo I and induce DNA damage–mediated cell death, while also blocking HER2 signaling and engaging ADCC.
YES
DIRECT
HER2-targeted ADC binds HER2, is internalized, and releases a topoisomerase I inhibitor payload that induces DNA damage–mediated cell death; it can also promote ADCC.
A HER2-targeted antibody–drug conjugate with a cleavable linker to a topoisomerase I inhibitor payload; binds HER2, internalizes, and releases the payload to induce DNA damage while retaining HER2 blockade and ADCC.
HER2-targeted monoclonal antibody conjugated via a cleavable linker to a topoisomerase I inhibitor; binds HER2 on tumor cells, internalizes, and releases the cytotoxic payload to inhibit Topo I and induce DNA damage–mediated cell death, while also blocking HER2 signaling and engaging ADCC.
NO
INDIRECT
The ADC binds HER2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that causes DNA damage and cell death; Topoisomerase I is the intracellular payload target, not the binding target, so Topoisomerase I–expressing cells alone are not selectively killed unless they are HER2-positive.
A HER2-targeted antibody–drug conjugate delivering the maytansinoid DM1 (microtubule inhibitor) via a non-cleavable linker; inhibits mitosis and mediates HER2 signaling blockade and ADCC.
HER2-targeted monoclonal antibody-drug conjugate (trastuzumab linked via a non-cleavable linker to the maytansinoid DM1). After binding HER2, it is internalized and degraded to release a DM1 catabolite that inhibits microtubules, causing mitotic arrest and apoptosis; the trastuzumab component also blocks HER2 signaling and mediates ADCC.
YES
DIRECT
T-DM1 binds HER2, is internalized, and lysosomal processing releases a DM1 catabolite that inhibits microtubules, causing mitotic arrest and apoptosis; Fc may also mediate ADCC.